S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Urgent alert: open this for a huge profit potential (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
He Is Giving Away Bitcoin (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Urgent alert: open this for a huge profit potential (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
He Is Giving Away Bitcoin (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Urgent alert: open this for a huge profit potential (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
He Is Giving Away Bitcoin (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Urgent alert: open this for a huge profit potential (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
How Biden has already won 2024 (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
He Is Giving Away Bitcoin (Ad)
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Shares of Walmart-backed Ibotta soar on public debut
Free Trial
OTCMKTS:IGXT

IntelGenx Technologies (IGXT) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)
Free IGXT Stock Alerts
$0.17
+0.01 (+6.25%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.17
▼
$0.18
50-Day Range
$0.14
▼
$0.19
52-Week Range
$0.09
▼
$0.22
Volume
73,325 shs
Average Volume
89,940 shs
Market Capitalization
$29.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest
IGXT stock logo

About IntelGenx Technologies Stock (OTCMKTS:IGXT)

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

IGXT Stock Price History

IGXT Stock News Headlines

April 11, 2024 | americanbankingnews.com
IntelGenx Technologies Corp. (OTCMKTS:IGXT) Short Interest Update
April 8, 2024 | finance.yahoo.com
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
April 19, 2024 | InvestorPlace (Ad)
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
April 8, 2024 | globenewswire.com
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial
April 5, 2024 | globenewswire.com
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
March 23, 2024 | seekingalpha.com
IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript
March 22, 2024 | insidermonkey.com
IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript
March 21, 2024 | investorplace.com
IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023
April 19, 2024 | InvestorPlace (Ad)
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 21, 2024 | globenewswire.com
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
March 16, 2024 | seekingalpha.com
IGXT IntelGenx Technologies Corp.
March 14, 2024 | globenewswire.com
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
March 11, 2024 | globenewswire.com
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
February 20, 2024 | finance.yahoo.com
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
February 20, 2024 | globenewswire.com
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
February 20, 2024 | globenewswire.com
IntelGenx Launches Preferred Share Regulation A Offering
February 19, 2024 | finance.yahoo.com
IntelGenx Technologies Corp. (IGXT)
February 5, 2024 | finance.yahoo.com
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform
December 7, 2023 | morningstar.com
Intelgenx Technologies Corp IGXT
November 14, 2023 | finance.yahoo.com
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
November 13, 2023 | finance.yahoo.com
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting
November 10, 2023 | insidermonkey.com
IntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call Transcript
November 9, 2023 | finance.yahoo.com
IntelGenx Reports Third Quarter 2023 Financial Results
November 6, 2023 | finance.yahoo.com
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray
September 21, 2023 | finance.yahoo.com
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
August 31, 2023 | finance.yahoo.com
IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)
August 16, 2023 | finanznachrichten.de
IntelGenx Technologies Corp.: IntelGenx Reports Second Quarter 2023 Financial Results
See More Headlines
Receive IGXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:IGXT
CUSIP
45822R101
CIK
1098880
Web
www.intelgenx.com
Phone
(514) 331-7440
Fax
514-331-0436
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,930,000.00
Net Margins
-955.44%
Pretax Margin
-955.44%
Return on Equity
N/A
Return on Assets
-128.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.41
Quick Ratio
0.40

Sales & Book Value

Annual Sales
$1.04 million
Price / Sales
28.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-2.43

Miscellaneous

Outstanding Shares
174,660,000
Free Float
101,214,000
Market Cap
$29.69 million
Optionable
Not Optionable
Beta
2.43
10 Best Stocks to Own in 2024 Cover
10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Dwight Gorham (Age 66)
    Chief Executive Officer
    Comp: $230.56k
  • Mr. Tommy Kenny J.D. (Age 37)
    L.L.B., M.Sc., Senior VP & General Counsel
    Comp: $152.62k
  • Ms. Nadine Paiement M.Sc. (Age 47)
    Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp
    Comp: $156.5k
  • Stephen Kilmer
    Investor Relations Officer
  • Ms. Ingrid Zerbe (Age 70)
    Corporate Secretary
  • Zenoz Nina Pourhassan
    VP of Quality Operations of Subsidiary

Key Competitors

View All Competitors

IGXT Stock Analysis - Frequently Asked Questions

How have IGXT shares performed in 2024?

IntelGenx Technologies' stock was trading at $0.1381 at the start of the year. Since then, IGXT shares have increased by 23.1% and is now trading at $0.17.
View the best growth stocks for 2024 here.

Are investors shorting IntelGenx Technologies?

IntelGenx Technologies saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 71,000 shares, an increase of 11,733.3% from the March 15th total of 600 shares. Based on an average trading volume of 213,700 shares, the days-to-cover ratio is presently 0.3 days.
View IntelGenx Technologies' Short Interest.

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.02) earnings per share for the quarter. The business earned $0.43 million during the quarter.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN).

How do I buy shares of IntelGenx Technologies?

Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IGXT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Urgent alert: open this for a huge profit potential
Timothy Sykes
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company